Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update

Rákkutatás · Ovarian cancer

For neoadjuvant chemotherapy (NACT), a platinum-taxane doublet is recommended.

The ASCO guideline update provides comprehensive, evidence‑based recommendations for the management of patients with newly diagnosed, stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. It covers patient selection, diagnostic work‑up, pre‑treatment testing, surgical strategy (primary cytoreductive surgery vs. neoadjuvant chemotherapy with interval cytoreductive surgery), choice of platinum‑taxane chemotherapy, perioperative adjuncts such as hyperthermic intraperitoneal chemotherapy, the role of maintenance therapy including bevacizumab, and strategies for patients who do not respond to initial chemotherapy. The guideline is based on a systematic review of 61 studies, including phase III RCTs, meta‑analyses and cohort studies, and offers a clear algorithm to guide clinical decision‑making.

Advancing ovarian cancer care hinges on identifying when neoadjuvant chemotherapy can be used to reduce tumor burden, improve surgical outcomes, and minimize perioperative morbidity while maintaining survival benefits. This updated guideline assists clinicians in making individualized, evidence‑based treatment decisions that enhance patient outcomes.

Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.

Eredeti forrás

Kapcsolódó jelek